Celularity Inc. (NASDAQ:CELU)

A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases. (NASDAQ:CELU)

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity secures strategic license deal worth up to $35M, strengthening capital position while focusing on longevity therapeutics.

Read the full release here:
https://t.co/FAWJfTEwoH

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity Inc. (Nasdaq: CELU) Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Read the full release here: https://t.co/dj5nl7IELT

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations

Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz.

https://t.co/wanvhwb5u0

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity announces the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

https://t.co/EOKIjCH7BZ

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

READ THE FULL RELEASE HERE:
https://t.co/UOodUZjgF3

[Celularity Inc. (NASDAQ:CELU) @celularity]

Big announcement! We are excited to be part of DefEYE’s focused expansion into the ophthalmic space and to demonstrate the transformative power of placental-derived regenerative biologic solutions.
Read the full release here: https://t.co/gTfopZhJNk

[Celularity Inc. (NASDAQ:CELU) @celularity]

Exciting news! Celularity Phase 2 clinical trial results published on the safety and efficacy of placenta-derived cells for diabetic foot ulcers complicated by Peripheral Artery Disease.
Read the full release here: https://t.co/xZR7NAdRBP

[Celularity Inc. (NASDAQ:CELU) @celularity]

We are pleased to report that we have filed our Form 10-Q quarterly reports for the first and the second quarters 2025. This comes on the heels of the recently announced retirement of all $32.0 million senior secured debt.

Read the full release here:
https://t.co/O7VSCBZTLY

[Celularity Inc. (NASDAQ:CELU) @celularity]

We have successfully monetized Celularity’s intellectual property assets to retire the Company’s senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses.

https://t.co/egoE03VLBq

[Celularity Inc. (NASDAQ:CELU) @celularity]

RELEASE: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Read it here:
https://t.co/PL4iZyihmu

[Celularity Inc. (NASDAQ:CELU) @celularity]

Release: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
https://t.co/7FTYITFY0t

[Celularity Inc. (NASDAQ:CELU) @celularity]

Advancing Ocular Surface Reconstruction: Our DDHAM-3L technology, with its unique biological properties, offers a promising platform for delivering patient-specific, iPSC-derived LSCs to restore vision and improve patient outcomes. https://t.co/ujDA5E4ri6

[Celularity Inc. (NASDAQ:CELU) @celularity]

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read the full release here: https://t.co/SFPNrYqN7b

[Celularity Inc. (NASDAQ:CELU) @celularity]

An important publication form our team in Frontiers in Immunology: Senescence, NK Cells, and Cancer.

Read the full release - with link to the publication - here:
https://t.co/a0pY6J7CtS

[Celularity Inc. (NASDAQ:CELU) @celularity]

Excited to receive FDA Tissue Reference Group recommendation letters on the newest additions to our portfolio of human placental-derived biomaterials. Full story here: https://t.co/Ho8JOH1MCy

[Celularity Inc. (NASDAQ:CELU) @celularity]

We are delighted to announce a strategic collaboration with BlueSphere Bio, Inc., which will bring together our core strengths in cell manufacturing, process development and BSB’s development of novel cell therapies to treat high risk leukemias. https://t.co/23dZ36Hkqx

[Celularity Inc. (NASDAQ:CELU) @celularity]

Celularity Founder and CEO Dr. Robert Hariri to be a Keynote Speaker at the Longevity Med Summit this May, discussing cellular therapies for human performance and longevity.
#longevity #stemcells
https://t.co/Zsy02wKA7P

[Celularity Inc. (NASDAQ:CELU) @celularity]

A great feature in Drug Target Review's Beyond the Lab Report on the work Celularity is doing in the realm of stem cell therapies. (Found on page 6.)
https://t.co/CPHfzvtCdJ

[Celularity Inc. (NASDAQ:CELU) @celularity]

Celularity, Inc. is proud to be a member of the MASS Coalition, a group of business leaders who together are working with the new administration to prevent amputation and other complications associated with Diabetes and Cardiovascular disease.  https://t.co/BFpB01qU3X

[Celularity Inc. (NASDAQ:CELU) @celularity]

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million!
Read the full release here:
https://t.co/7F5Twpn41P